Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Menarini and OBT Sign Major Strategic Collaboration

Published: Tuesday, October 30, 2012
Last Updated: Tuesday, October 30, 2012
Bookmark and Share
Strategic alliance for the clinical development and manufacture of a portfolio of novel antibody-based cancer drugs.

Menarini and Oxford BioTherapeutics (OBT) have announced a major innovative and strategic alliance to develop a portfolio of antibody-based drugs in the field of cancer.

The agreement covers five of OBT’s antibody and antibody drug conjugate (ADC) programs, each of which addresses a different cancer indication via a different novel oncology target.

The deal brings together OBT’s discovery expertise with Menarini’s clinical knowledge, and expanding capabilities in the manufacture and development of biologics, to build value for both companies as they work to bring this exciting portfolio of next generation antibody-based cancer drugs to market.

Under the collaboration, Menarini will lead the efforts in the manufacture and clinical development of each program, supported by OBT, while OBT will provide the proprietary cancer target, antibody and arming technologies.

Once clinical proof of concept has been achieved, OBT will complete the clinical development and commercialize these novel antibody-based products in North America and Japan, whilst Menarini will develop and commercialize the products in Europe, CIS, Asia and Latin America.

Christian Rohlff, CEO of OBT, commented, “I am delighted to collaborate with Menarini, a company that has made impressive achievements in biologics development and demonstrated an enduring commitment to the development of innovative cancer therapies. This creative alliance is transformational for us as it allows OBT to participate in the clinical development and future commercialization of our programs while at the same time it bolsters Menarini’s pipeline with a portfolio of the next generation of cancer drugs. We believe this innovative business framework could become the business model of choice for rapidly growing biotechnology companies seeking new ways to develop their drug pipeline effectively.”

Alberto Giovanni Aleotti, member of the Board of A. Menarini, commented, “We are eager to start our collaboration with OBT, an oncology company with a proven track record of generating innovative antibody-based cancer drug candidates that are designed to address high unmet medical needs. I am very pleased that this novel strategic alliance, which foresees the development and manufacture of up to 5 cancer treatment programs and a total investment of 800 million Euro, will enable us to further demonstrate our deep and long standing commitment to the fight against cancer, which has always been crucial to Menarini’s overall corporate mission.”

OBT’s dedicated development operation in Basel, Switzerland, established in May 2012 under the direction of COO Dr. Esteban Pombo, will perform a central role in supporting the new collaboration as OBT and Menarini work together to progress OBT’s most advanced therapeutic antibody and antibody drug conjugate (ADC) oncology programs into clinical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford BioTherapeutics Appoints Dr Eugen Leo
Dr. Leo will be responsible for driving the Company’s pipeline of ADCs into clinical development.
Thursday, July 10, 2014
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
Company to develop novel antibody-drug conjugate for HER2-negative breast cancer.
Friday, May 16, 2014
OBT and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia
First clinical development candidate in $1 billion oncology investment alliance.
Thursday, January 02, 2014
OBT and Boehringer Ingelheim Enter Collaboration
Collaboration to discover novel antibody targets in cancer.
Monday, April 29, 2013
Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™
Agreement covers the research, development and commercial use of the GS System™ by Oxford BioTherapeutics.
Monday, September 05, 2011
Scientific News
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!